Where Immunocore Hldgs Stands With Analysts
Portfolio Pulse from Benzinga Insights
Immunocore Holdings (NASDAQ:IMCR) has received mixed analyst ratings over the past three months, with a recent shift towards more bullish perspectives. The average 12-month price target for IMCR has increased to $81.4, up from $72.60, indicating a positive outlook from analysts. Key financial metrics such as revenue growth, net margin, ROE, and ROA have shown strong performance, with the company outperforming industry averages. Analysts from firms like Leerink Partners, Guggenheim, Needham, JP Morgan, HC Wainwright & Co., Mizuho, Oppenheimer, and Canaccord Genuity have updated their ratings and price targets, reflecting optimism about IMCR's market position and financial health.
April 29, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immunocore Holdings has seen a positive shift in analyst ratings, with an increased average price target of $81.4, indicating a bullish outlook. The company's strong financial performance, including a revenue growth rate of 34.25% and superior metrics like net margin and ROE, supports this optimism.
The increase in the average price target to $81.4 from $72.60, along with positive adjustments in ratings and price targets by several analysts, reflects growing confidence in Immunocore's market position and financial health. The company's strong financial metrics, such as a 34.25% revenue growth rate, exceptional net margin, and impressive ROE and ROA, further bolster the bullish sentiment among analysts. This collective optimism and the company's performance metrics are likely to have a positive short-term impact on IMCR's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100